Sources: Canadian Pharma IPR Changes In CETA Align With TPP Rules

The two major changes Canada will need to make to its pharmaceutical intellectual property rights laws in order to meet its obligations under the Comprehensive Economic and Trade Agreement with the European Union will also bring Ottawa into compliance with its Trans-Pacific Partnership obligations, sources told Inside U.S. Trade this week. First, Canada will have to provide a patent term extension of two years for pharmaceutical products to account for administrative delays in marketing approval. Canada currently does not...